Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Novartis Hopes For Canakinumab In Lung Cancer Nosedive

Second Phase III Fail In NSCLC

Executive Summary

After deciding to examine canakinumab's potential in lung cancer on the back of the CANTOS cardiovascular trial, Novartis designed a major late-stage program in oncology for the interleukin-1 beta inhibitor. The second of those CANOPY trials has just come crashing down.

You may also be interested in...



Novartis's Tislelizumab Takes First Step On US Approval Path

Novartis has filed the PD-1 inhibitor tislelizumab, licensed from BeiGene, for second-line esophageal cancer with the FDA, the first submission outside China for the closely-watched therapy.

Wider Than AZ’s PACIFIC – Novartis Has Broad NSCLC Plans For Canakinumab

Novartis is taking its unexpected CANTOS cancer findings for canakinumab and running with them to Phase III in an adjuvant lung cancer setting that is broader that AstraZeneca's PACIFIC study.

CANTOS: Modest CV And Intriguing Lung Cancer Benefit With Canakinumab

With CANTOS, Novartis's canakinumab has become the first investigational treatment to show that selectively targeting inflammation significantly reduces cardiovascular risk, albeit modestly, but with the added bonus of reducing lung cancer.

Topics

Related Companies

UsernamePublicRestriction

Register

SC145288

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel